Shop research vials with the spec in view.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.

Retatrutide is a once-weekly triple GLP-1/GIP/glucagon receptor agonist — Phase 2 data showed 24.2% mean body weight reduction at 48 weeks, the highest result in obesity pharmacology Phase 2 trial history at publication.

Thymosin Beta 4 (TB-500) is a 43-amino-acid actin-sequestering peptide studied in preclinical models for cardiac repair, wound healing, tissue regeneration, and anti-inflammatory activity.

MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.

Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.

Bacteriostatic Water is 0.9% benzyl alcohol in sterile water for injection — the standard multi-dose-stable reconstitution vehicle for lyophilized research peptides.